Lung Cancer
Lung Cancer: Recent Genomics Insights - April 30, 2015
CDC and Related Info
- What you can do to lower your lung cancer risk
- A family history of lung cancer is a risk factor for lung cancer
- Genes reported in relation to lung cancer, including genomewide association studies via theHuGE Navigator
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
Jänne PA et al. N. Engl. J. Med. 2015 Apr 30. (18) 1689-1699
Jänne PA et al. N. Engl. J. Med. 2015 Apr 30. (18) 1689-1699
Rociletinib in EGFR-mutated non-small-cell lung cancer.
Sequist LV et al. N. Engl. J. Med. 2015 Apr 30. (18) 1700-1709
Sequist LV et al. N. Engl. J. Med. 2015 Apr 30. (18) 1700-1709
Overcoming resistance to targeted therapy for lung cancer.
Govindan R et al. N. Engl. J. Med. 2015 Apr 30. (18) 1760-1761
Govindan R et al. N. Engl. J. Med. 2015 Apr 30. (18) 1760-1761
Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR.
Richer AL et al. Pharmgenomics Pers Med 2015 63-79
Richer AL et al. Pharmgenomics Pers Med 2015 63-79
Genomics driven-oncology: challenges and perspectives.
Normanno N et al. BMC Cancer 2015 141
Normanno N et al. BMC Cancer 2015 141
BRAF mutations in non-small cell lung cancer.
Luk PP et al. Transl Lung Cancer Res 2015 Apr (2) 142-8
Luk PP et al. Transl Lung Cancer Res 2015 Apr (2) 142-8
The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer.
Wang S et al. Transl Lung Cancer Res 2015 Apr (2) 119-25
Wang S et al. Transl Lung Cancer Res 2015 Apr (2) 119-25
Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing.
Iwakawa R et al. Carcinogenesis 2015 Apr 11.
Iwakawa R et al. Carcinogenesis 2015 Apr 11.
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.
Oser MG et al. Lancet Oncol. 2015 Apr (4) e165-e172
Oser MG et al. Lancet Oncol. 2015 Apr (4) e165-e172
Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy.
Mok TS et al. Clin. Cancer Res. 2015 Mar 31.
Mok TS et al. Clin. Cancer Res. 2015 Mar 31.
Genetic variants of the MDM2 gene are predictive of treatment-related toxicities and overall survival in patients with advanced NSCLC.
Qian J et al. Clin Lung Cancer 2015 Feb 19.
Qian J et al. Clin Lung Cancer 2015 Feb 19.
The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer.
Lewandowska MA et al. PLoS ONE 2015 (2) e0117983
Lewandowska MA et al. PLoS ONE 2015 (2) e0117983
Oncologists push beyond new lung cancer genomic testing guidelines.
Garber K et al. J. Natl. Cancer Inst. 2015 Feb (2)
Garber K et al. J. Natl. Cancer Inst. 2015 Feb (2)
Lung Cancer: Smoking, Genomics and Family History - November 6, 2014
CDC information: What you can do to lower your lung cancer risk
CDC information: A family history of lung cancer is a risk factor for lung cancer
Did you know? 1202 genes have been reported in relation to risk and outcomes of lung cancer, including 74 genomewide association studies. To find out more, visit the HuGE Navigator
American Cancer Society- Why lung cancer strikes nonsmokers- risk factors include genetics
Recent Insights
Common genetic variants on 3q28 contribute to non-small cell lung cancer susceptibility: evidence from 10 case-control studies.
Jin YX, et al. Mol Genet Genomics. 2014 Oct 25
Jin YX, et al. Mol Genet Genomics. 2014 Oct 25
Small cell lung cancer: Where do we go from here?
Byers LA, et al. Cancer. 2014 Oct 21.
Byers LA, et al. Cancer. 2014 Oct 21.
Association between the CYP2E1 polymorphisms and lung cancer risk: a meta-analysis.
Ye XH, et al. Mol Genet Genomics. 2014 Oct 22.
Ye XH, et al. Mol Genet Genomics. 2014 Oct 22.
Therapeutic use of micrornas in lung cancer.
Fortunato O, et al. Biomed Res Int. 2014;2014:756975. Review
Fortunato O, et al. Biomed Res Int. 2014;2014:756975. Review
Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.
Yap TA, et al. Pharmgenomics Pers Med. 2014 Sep 19;7:285-95.
Yap TA, et al. Pharmgenomics Pers Med. 2014 Sep 19;7:285-95.
The expression of four genes as a prognostic classifier for stage I Lung Adenocarcinoma in 12 independent cohorts.
Okayama H, et al. Cancer Epidemiol Biomarkers Prev. 2014 Sep 21
Okayama H, et al. Cancer Epidemiol Biomarkers Prev. 2014 Sep 21
Lung Cancer: Genomic Tests and Improved Outcomes - May 29, 2014
National Cancer Institute: Lung cancer is the leading cause of cancer death in men & women.Here's what you need to know
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Kris MG, et al. JAMA. 2014 May 21;311(19):1998-2006.
Kris MG, et al. JAMA. 2014 May 21;311(19):1998-2006.
Non–small cell lung cancer and precision medicine: A model for the incorporation of genomic features into clinical trial design
Pasche B, et al. JAMA 2014 May 12
Pasche B, et al. JAMA 2014 May 12
Personalized medicine boost lung cancer survival, Phillipa Brice, PHG Foundation, May 23
Phillipa Brice, PHG Foundation, May 23
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis
Westwood M, et al. Health Technol Assess 2014 May;18(32):1-166
Westwood M, et al. Health Technol Assess 2014 May;18(32):1-166
Find out which genomic tests for lung cancer can improve health and affect survival (tier 1), visit the CDC Table of genomic applications by level of evidence and look for lung cancer entries
.png)
No hay comentarios:
Publicar un comentario